Literature DB >> 17415633

Bone morphogenetic protein 7 is elevated in patients with chronic liver disease and exerts fibrogenic effects on human hepatic stellate cells.

Frank Tacke1, Erwin Gäbele, Frauke Bataille, Robert F Schwabe, Claus Hellerbrand, Frank Klebl, Rainer H Straub, Tom Luedde, Michael P Manns, Christian Trautwein, David A Brenner, Jürgen Schölmerich, Bernd Schnabl.   

Abstract

Hepatic stellate cells (HSCs) are the main extracellular matrix (ECM)-producing cells in liver fibrogenesis. The excessive synthesis of ECM proteins deteriorates hepatic architecture and results in liver fibrosis and cirrhosis. This study investigated the role of bone morphogenetic protein 7 (BMP7) as a member of the transforming growth factor (TGF)-beta superfamily in chronic liver disease. Plasma levels of BMP7 were significantly elevated in patients with chronic liver disease compared with healthy controls. Immunohistochemistry of cirrhotic human liver demonstrated upregulated BMP7 protein expression in hepatocytes as compared with normal human liver. Because gene expression for all putative BMP7 receptors was induced during the culture activation process of primary human HSCs, we studied the effects of BMP7 on hTERT immortalized human HSCs in vitro. BMP7, as expressed and secreted after infection with adenoviruses encoding BMP7 (AdBMP7), increased proliferation of HSCs. The mRNA and protein expression of type I collagen and fibronectin was increased in BMP7-stimulated HSCs. Elevated systemic and hepatic levels of BMP7 in patients with chronic liver disease may contribute to progression of liver fibrogenesis in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17415633     DOI: 10.1007/s10620-007-9758-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  43 in total

Review 1.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus.

Authors:  Yigong Shi; Joan Massagué
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

2.  Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome inhibitors and an IkappaB super-repressor.

Authors:  C Hellerbrand; C Jobin; Y Iimuro; L Licato; R B Sartor; D A Brenner
Journal:  Hepatology       Date:  1998-05       Impact factor: 17.425

3.  Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction.

Authors:  K A Hruska; G Guo; M Wozniak; D Martin; S Miller; H Liapis; K Loveday; S Klahr; T K Sampath; J Morrissey
Journal:  Am J Physiol Renal Physiol       Date:  2000-07

4.  c-Jun-N-terminal kinase drives cyclin D1 expression and proliferation during liver regeneration.

Authors:  Robert F Schwabe; Cynthia A Bradham; Tetsuya Uehara; Etsuro Hatano; Brydon L Bennett; Robert Schoonhoven; David A Brenner
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

5.  Gene therapy for bone formation: in vitro and in vivo osteogenic activity of an adenovirus expressing BMP7.

Authors:  R T Franceschi; D Wang; P H Krebsbach; R B Rutherford
Journal:  J Cell Biochem       Date:  2000-06-06       Impact factor: 4.429

6.  Bone morphogenetic protein-7 inhibits constitutive and interleukin-1 beta-induced monocyte chemoattractant protein-1 expression in human mesangial cells: role for JNK/AP-1 pathway.

Authors:  Myung-Ja Lee; Chul Woo Yang; Dong Chan Jin; Yoon Sik Chang; Byung Kee Bang; Yong-Soo Kim
Journal:  J Immunol       Date:  2003-03-01       Impact factor: 5.422

7.  Antisense inhibition of osteogenic protein 1 disturbs human articular cartilage integrity.

Authors:  Stephan Söder; Arnavaz Hakimiyan; David C Rueger; Klaus E Kuettner; Thomas Aigner; Susan Chubinskaya
Journal:  Arthritis Rheum       Date:  2005-02

8.  p38MAPK acts in the BMP7-dependent stimulatory pathway during epithelial cell morphogenesis and is regulated by Smad1.

Authors:  Ming Chang Hu; David Wasserman; Sunny Hartwig; Norman D Rosenblum
Journal:  J Biol Chem       Date:  2004-01-12       Impact factor: 5.157

9.  Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat.

Authors:  S Vukicevic; V Basic; D Rogic; N Basic; M S Shih; A Shepard; D Jin; B Dattatreyamurty; W Jones; H Dorai; S Ryan; D Griffiths; J Maliakal; M Jelic; M Pastorcic; A Stavljenic; T K Sampath
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

10.  Effects of osteogenic protein-1 (OP-1, BMP-7) on gene expression in cultured medial collateral ligament cells.

Authors:  Alicia D Tsai; Lee-Chuan C Yeh; John C Lee
Journal:  J Cell Biochem       Date:  2003-11-01       Impact factor: 4.429

View more
  25 in total

1.  Non-invasive biomarkers for monitoring the fibrogenic process in liver: a short survey.

Authors:  Axel-M Gressner; Chun-Fang Gao; Olav-A Gressner
Journal:  World J Gastroenterol       Date:  2009-05-28       Impact factor: 5.742

2.  Cultivating hepatocytes on printed arrays of HGF and BMP7 to characterize protective effects of these growth factors during in vitro alcohol injury.

Authors:  Caroline N Jones; Nazgul Tuleuova; Ji Youn Lee; Erlan Ramanculov; A Hari Reddi; Mark A Zern; Alexander Revzin
Journal:  Biomaterials       Date:  2010-05-21       Impact factor: 12.479

3.  Suppression of hepatocyte proliferation by hepatocyte nuclear factor 4α in adult mice.

Authors:  Jessica A Bonzo; Christina H Ferry; Tsutomu Matsubara; Jung-Hwan Kim; Frank J Gonzalez
Journal:  J Biol Chem       Date:  2012-01-12       Impact factor: 5.157

4.  Enteric dysbiosis associated with a mouse model of alcoholic liver disease.

Authors:  Arthur W Yan; Derrick E Fouts; Johannes Brandl; Peter Stärkel; Manolito Torralba; Eckart Schott; Hide Tsukamoto; Karen E Nelson; David A Brenner; Bernd Schnabl
Journal:  Hepatology       Date:  2010-12-10       Impact factor: 17.425

5.  CXCL5 plasma levels decrease in patients with chronic liver disease.

Authors:  Frank Tacke; Henning W Zimmermann; Christian Trautwein; Bernd Schnabl
Journal:  J Gastroenterol Hepatol       Date:  2011-03       Impact factor: 4.029

6.  Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis.

Authors:  Henning W Zimmermann; Sebastian Seidler; Jacob Nattermann; Nikolaus Gassler; Claus Hellerbrand; Alma Zernecke; Jens J W Tischendorf; Tom Luedde; Ralf Weiskirchen; Christian Trautwein; Frank Tacke
Journal:  PLoS One       Date:  2010-06-10       Impact factor: 3.240

7.  Deficiency of intestinal mucin-2 protects mice from diet-induced fatty liver disease and obesity.

Authors:  Phillipp Hartmann; Caroline T Seebauer; Magdalena Mazagova; Angela Horvath; Lirui Wang; Cristina Llorente; Nissi M Varki; Katharina Brandl; Samuel B Ho; Bernd Schnabl
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-12-23       Impact factor: 4.052

8.  Inhibitory effect of bone morphogenetic protein-7 on hepatic fibrosis in rats.

Authors:  Sheng-Lan Wang; Chang-Qing Yang; Xiao-Long Qi; Min Yuan; Yi-Zhong Chang; Li Yang; Heng-Jun Gao
Journal:  Int J Clin Exp Pathol       Date:  2013-04-15

9.  Exogenous BMP7 corrects plasma iron overload and bone loss in Bmp6-/- mice.

Authors:  Martina Pauk; Lovorka Grgurevic; Jelena Brkljacic; Vera Kufner; Tatjana Bordukalo-Niksic; Kristina Grabusic; Genadij Razdorov; Dunja Rogic; Marijan Zuvic; Hermann Oppermann; Jodie L Babitt; Herbert Y Lin; Sinisa Volarevic; Slobodan Vukicevic
Journal:  Int Orthop       Date:  2014-10-11       Impact factor: 3.075

Review 10.  Bone morphogenetic protein-7 and connective tissue growth factor: novel targets for treatment of renal fibrosis?

Authors:  Tri Q Nguyen; Roel Goldschmeding
Journal:  Pharm Res       Date:  2008-02-12       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.